1. Home
  2. Companies
  3. RAC
  4. Material Events

Racura Oncology (ASX:RAC) — Material Events

ASX:RAC · 27 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 19 articles Notable 6 articles Routine 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
19
Race Oncology Advances RC220 Trial with Korean IND ApprovalMedium
Race Oncology Secures Korean MFDS IND Approval for RC220 Phase 1 Trial
24 Sept 2025 ·Regulatory Approval Announcement ·85
Racura Oncology Secures $34.3 Million to Fully Fund Three Cancer TrialsMedium
Racura Oncology Raises $34.3 Million to Fund Three Oncology Clinical Trials
16 June 2026 ·Capital Raising ·85
Racura Oncology Advances Lung Cancer Trials with $34.3 Million Cash BackingMedium
Racura Oncology advances clinical trials and secures $34.3M cash runway into 2028
28 July 2026 ·Quarterly Activity Report & Appendix 4C ·85
Race Oncology Unveils Breakthrough Mechanism for Lead Drug Targeting MYC OncogeneMedium
Race Oncology reveals novel G4-DNA/RNA binding mechanism for anticancer drug (E,E)-bisantrene targeting MYC oncogene
2 Oct 2025 ·ASX Announcement ·Unexpected ·85
Racura Oncology Unveils Breakthroughs and $20.9m Cash to Fuel Cancer TrialsHigh
Racura Oncology advances clinical programs and patents with $20.94m cash and $3.22m placement
29 Jan 2026 ·Quarterly Activity Report & Appendix 4C ·85
Race Oncology Secures 20-Year Patent on Active Bisantrene IsomerMedium
Race Oncology Files Patents for Active (E,E)-Bisantrene Isomer, Securing IP Protection Until 2045
16 Sept 2025 ·ASX Announcement ·85
Race Oncology Secures 20-Year Patent Edge with Bisantrene BreakthroughHigh
Race Oncology files key patents on active bisantrene isomer, advances Phase 1 trial, and strengthens cash position
31 Oct 2025 ·Quarterly Activity Report & Appendix 4C ·Unexpected ·85
Race Oncology Unveils Dual Cardioprotective and Anticancer Promise of RC220 at ESMO 2025Medium
Race Oncology presents dual cardioprotective and anticancer benefits of RC220 with doxorubicin at ESMO 2025
20 Oct 2025 ·ASX Announcement ·85
Racura Oncology Accelerates Cardioprotection Trial with Novel Blood TestMedium
Racura Oncology advances cardioprotection trial with novel blood test, accelerating data collection by two years
11 Feb 2026 ·Clinical Trial Update ·80
Racura Oncology’s $4.1M Loss Highlights Clinical and Patent AdvancesMedium
Racura Oncology reports $4.1M half-year loss amid clinical progress and capital raises
27 Feb 2026 ·Appendix 4D Half-year report ·Unexpected ·80
Racura Oncology Advances Lung Cancer Trials with Strong Cash BackingMedium
Racura Oncology advances clinical trials and research with strong cash position in Q3 FY2026
30 Apr 2026 ·Quarterly Activity Report & Appendix 4C ·80
Racura Oncology Teams with Emory to Tackle Osimertinib Resistance in Lung CancerMedium
Racura Oncology partners with Emory University to advance osimertinib-resistant lung cancer treatment
14 Jan 2026 ·Collaboration Announcement ·80
Racura Oncology Unveils Mechanism Behind MYC Gene Silencing by (E,E)-bisantrene at AACR 2026Medium
Racura Oncology presents data showing (E,E)-bisantrene silences MYC gene at AACR 2026
22 Apr 2026 ·Scientific Data Presentation ·75
Racura Oncology Recruits First Patient for Pioneering Lung Cancer TrialMedium
Racura Oncology recruits first patient for Phase 1 HARNESS-1 lung cancer trial
31 Mar 2026 ·Clinical Trial Update ·75
Racura Oncology Expands CPACS Trial to Korea with Three Premier Sites ActivatedMedium
Racura Oncology Opens Korean Sites for CPACS Trial Patient Enrolment
1 Sept 2026 ·Clinical Trial Update ·75
Race Oncology Secures Ethics Nod for Pioneering Lung Cancer TrialMedium
Race Oncology Gets Ethics Approval for Phase 1a/b Lung Cancer Trial of RC220
26 Nov 2025 ·Clinical Trial Announcement ·75
Racura Oncology Reports $11.1M Loss Amid Major MYC Gene Breakthrough and Clinical AdvancesMedium
Racura Oncology reports $11.1M loss, advances MYC-targeting cancer drug with strong funding
25 Aug 2026 ·Annual Report ·75
Racura Oncology Advances Lung Cancer Fight with RC220 Trial ApprovalMedium
Racura Oncology Gets Approval to Start Phase 1 Lung Cancer Trial Combining RC220 with Osimertinib
16 Mar 2026 ·Clinical Trial Approval Announcement ·75
Race Oncology Secures $3.22m to Launch HARNESS-1 Lung Cancer TrialMedium
Race Oncology Raises $3.22m to Fund HARNESS-1 Lung Cancer Trial Starting Early 2026
9 Dec 2025 ·Capital Raising ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.